^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NC318

    i
    Other names: NC318, NC 318, NC-318
    Company:
    NextCure
    Drug class:
    SIGLEC15 inhibitor
    Related drugs:
    10ms
    The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=159, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • NC318
    over2years
    NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC (IASLC-WCLC 2023)
    NC318 alone (800 mg IV weekly) and in combination (NC318 400 mg IV every 2 weeks) with standard dosing of pembrolizumab is well tolerated and has activity in pts previously treated with PD1 axis inhibitor therapy. Pts continue to accrue to NC318 800 mg IV weekly, with an additional arm evaluating combination therapy with NC318 800 mg IV weekly and pembrolizumab 200 mg IV every 3 weeks planned.
    Combination therapy
    |
    SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
    |
    Keytruda (pembrolizumab) • NC318
    over2years
    A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=109, Completed, NextCure, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    NC318
    over4years
    The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=141, Recruiting, Yale University | N=97 --> 141
    Clinical • Enrollment change • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • NC318
    over4years
    The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=97, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • NC318
    over4years
    A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, NextCure, Inc. | N=165 --> 0 | Not yet recruiting --> Withdrawn
    Clinical • Enrollment change • Trial withdrawal • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • NC318
    5years
    The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=97, Not yet recruiting, Yale University
    Clinical • New P2 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • NC318
    over5years
    A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=165, Not yet recruiting, NextCure, Inc.
    Clinical • New P1/2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • NC318